A new study of over 400 patients with left ventricular assist devices adds to the mixed evidence on atrial arrhythmias in this population and provides the first systematic look at the effects of rhythm control.
Our electrophysiologists share their approach to deciding between ablation and medical management along with a wealth of insights for care before and after the ablation procedure.
Debate around findings of the multicenter CABANA study of ablation versus drug therapy for atrial fibrillation shouldn’t distract from why patients seek ablation in the first place: symptom relief.
Our funded projects include a study of interactions among genomics, aging and metabolism and a clinical trial of metformin and lifestyle modifications for reducing AF burden.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
As the use of LVADs for destination therapy grows, a new study offers the first guidance on whether aggressive treatment for atrial arrhythmias makes a difference in this setting.
A new study identified genes and genetic variations associated with 12 loci linked to risk for atrial fibrillation. The result is a genome-wide catalog to facilitate follow-on investigations.
Dr. Oussama Wazni suspects more patients with AF could benefit from early catheter ablation. So he’s leading two multicenter trials to see if his suspicions pan out.
A study shows that the first FDA-approved smartwatch healthcare accessory can effectively identify atrial fibrillation, especially with physician overview. But incorporating it into practice won’t be simple.
Middle-aged pro football retirees have a 5.5 odds ratio of prevalent atrial fibrillation compared with matched nonathlete controls from the general population, a new study finds.
Fewer than half of cardiac surgery patients with atrial fibrillation undergo concomitant ablation. Here’s why that fact is so inexplicable in 2018.